REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue recognition	$ 83,821	$ 52,061	$ 222,153	$ 155,207
Sales of generic pharmaceutical products
Revenue recognition	53,136	35,140	152,106	101,952
Sales of established brand pharmaceutical products
Revenue recognition	9,816	14,313	26,731	32,868
Sales of rare disease pharmaceutical products
Revenue recognition	12,602		24,096
Sales of contract manufactured products
Revenue recognition	4,779	2,382	12,072	7,277
Royalties from licensing agreements
Revenue recognition	1,821		3,918	11,210
Product development services
Revenue recognition	1,503	77	2,600	332
Other
Revenue recognition	$ 164	$ 149	$ 630	$ 1,568